Gilead Sciences | GILD - Net Income


Gilead Sciences reported $2.02B in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
ALKERMES USD -66.48M 115.82M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Incyte USD 303.33M 4.05M Mar/2026
J&J USD 5.24B 119M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026